

Application No. 09/744,622  
Amendment dated August 31, 2006  
Non-Compliant Amendment Dated June 6, 2006

Docket No.: HO-P01615US1

AMENDMENTS TO THE CLAIMS

RECEIVED  
CENTRAL FAX CENTER  
AUG 31 2006

Claims 1-99 (Canceled)

100. (currently amended) A method for inducing intracellular hyperthermia in a subject comprising the step of administering an amount of a mitochondrial uncoupling agent sufficient to the subject to induce whole body intracellular hyperthermia in the subject, wherein the induced intracellular hyperthermia is used to treat ~~or diagnose~~ cancer selected from the group consisting of prostate carcinoma, glioblastoma multiform, Kaposi's sarcoma, peritoneal carcinomatosis, and glioma.
101. (previously presented) The method of claim 100, wherein the mitochondrial uncoupling agent is 2,4 dinitrophenol.
102. (canceled)
103. (previously presented) The method of claim 100, wherein the mitochondrial uncoupling agent is a conjugate comprising 2,4 dinitrophenol.
104. (previously presented) The method of claim 100, wherein an animal is administered the mitochondrial uncoupling agent and a separate medication is administered, wherein the second medication increases the overall metabolic rate of the animal, the metabolic rate of a specific target tissue in the animal, or an increase in free radical flux.
105. (previously presented) The method of claim 104, wherein the second medication is selected from the group consisting of glucagon, arbutamine, dobutamine, vasopressin, glutamine, proline, octanoate, methylene blue (tetramethylthionine), ubiquinone, menadione, hematoporphyrin, polyunsaturated fatty acids, monounsaturated fatty acids and a combination thereof.
106. (previously presented) The method of claim 100, wherein the induced intracellular hyperthermia involve the induction of heat shock proteins.
107. (previously presented) The method of claim 100 further comprising administering an anti-cancer agent selected from the group consisting of metholtrexate, mercaptopuorine, fluorouracil, cytarabine, thioguanine, azacitidine, etoposide (VP-16) and teniposide (VM-

25691855.1

325. 11/11/06 10:00

Application No. 09/744,622  
Amendment dated August 31, 2006  
Non-Compliant Amendment Dated June 6, 2006

Docket No.: HO-P01615US1

- 26), vincristine, vinblastine, paclitaxel, busulfan, cyclophosphamide, mechlorethamine, melphalan, altaretamine, ifosfamide, cisplatin, dacarbazine, procarbazine, lomustine, carmustine, lomustine, semustine, chlorambucil, thiotepa, carboplatin; flutamide, prednisone, ethinyl estradiol, diethylstilbestrol, hydroxyprogesterone caproate, medroxyprogesterone, megestrolacetate, testosterone, fluoxymesterone, diiodothyroidine, triiodothyroidine, tetraiodothyroidine, aromatase inhibitor, amino glutethimide, octreotide, goserilin acetate, leuprolide, interferon alpha-2a, interferon alpha-2b, interferon-gamma, interferon-beta, interleukin-1, interleukin-2, interleukin-4, interleukin-10, anti-HER-2/neu humanized antibody, tumor necrosis factor, granulocyte-macrophage colony-stimulating factor, macrophage-colony-stimulating factor, phenylacetates, retinoic acids, leukotrienes, thromboxanes, and a combination thereof.
108. (previously presented) The method of claim 100 further comprising administering radiation.
109. (currently amended) A method for inducing intracellular hyperthermia in a subject comprising the step of administering an amount of a mitochondrial uncoupling agent sufficient to the subject to induce whole body intracellular hyperthermia in the subject, wherein the induced intracellular hyperthermia is used to treat or diagnose infections that result from *Borrelia burgdorferi*, *Mycobacterium leprae*, *Treponema pallidum*, HIV, hepatitis C, herpes virus or papillomavirus.
110. (previously presented) The method of claim 109, wherein the mitochondrial uncoupling agent is 2,4 dinitrophenol.
111. (previously presented) The method of claim 109, wherein the mitochondrial uncoupling agent is a conjugate comprising 2,4 dinitrophenol.
112. (previously presented) The method of claim 109, wherein an animal is administered the mitochondrial uncoupling agent and a separate medication is administered, wherein the second medication increases the overall metabolic rate of the animal, the metabolic rate of a specific target tissue in the animal, or an increase in free radical flux.
113. (previously presented) The method of claim 109, wherein the induced intracellular hyperthermia involve the induction of heat shock proteins.

25691855.1

3

Application No. 09/744,622  
Amendment dated August 31, 2006  
Non-Compliant Amendment Dated June 6, 2006

Docket No.: HO-P01615US1

114. (previously presented) The method of claim 109 further comprising administering an anti-bacterial agent selected from the consisting of betalactam, macrolide, tetracycline, aminoglycoside, peptide antibiotic, sulfonamide, quinolone, nucleoside, oligosaccharide, polyene, nitrofurantoin, and a combination thereof.
115. (previously presented) The method of claim 109 further comprising administering an antiviral agent selected from the group consisting of amantadine, rimantadine, arildone, ribavirin, acyclovir, abacavir, vidarabine (ARA-A) 9-1,3-dihydroxy-2-propoxy methylguanine (DHPG), ganciclovir, enviroxime, foscarnet, amplitagen, podophyllotoxin, 2,3-dideoxythymidine (ddQ), iododeoxyuridine (IDU), trifluorothymidine (TFT), dideoxymosine (ddi), d4T, 3TC, zidovudine, efavirenz, indinavir, saquinavir, ritonavir, nelfinavir, amprenavir, and a combination thereof.
116. (currently amended) A method for inducing intracellular hyperthermia in a subject comprising the step of administering an amount of a mitochondrial uncoupling agent sufficient to the subject to induce whole body intracellular hyperthermia in the subject, wherein the induced intracellular hyperthermia is used to treat or ~~diagnose~~ an infestation that results from *Candida*, *Sporothrix schenckii*, *Histoplasma*, *paracoccidioides*, *Aspergillus*, *Leishmania*, malaria, *acanthamoeba* or cestodes.
117. (previously presented) The method of claim 116 further comprising administering an antifungal agent selected from the group consisting of Amphotericin B, Griseofulvin, Fluconazole (Diflucan), Itraconazole, 5 fluoro-cytosine (Flutocytosine, 5-FC), Ketatoconazole and Miconazole.
118. (previously presented) The method of claim 116, wherein the mitochondrial uncoupling agent is 2,4 dinitrophenol.
119. (previously presented) The method of claim 116, wherein the mitochondrial uncoupling agent is a conjugate comprising 2,4 dinitrophenol.
120. (previously presented) The method of claim 116, wherein an animal is administered the mitochondrial uncoupling agent and a separate medication is administered, wherein the second medication increases the overall metabolic rate of the animal, the metabolic rate of a specific target tissue in the animal, or an increase in free radical flux.

25691855.1

4

Application No. 09/744,622  
Amendment dated August 31, 2006  
Non-Compliant Amendment Dated June 6, 2006

Docket No.: HO-P01615US1

121. (previously presented) The method of claim 116, wherein the induced intracellular hyperthermia involve the induction of heat shock proteins.

25691855.1

5